Evolutionary Dynamics: Unleashing the Potential of Cell and Gene Therapy Manufacturing Market
Genesis and Transformations
The narrative of cell and gene therapy manufacturing market unfolds as a saga of evolution and transformation. From its inception to the contemporary landscape, the sector has witnessed significant advancements, reshaping the contours of medical innovation.
Market Size Revelation: Navigating Financial Horizons
Commencing at USD 3,755.4 million in 2022, the cell and gene therapy manufacturing market is poised to unveil an unprecedented financial horizon, reaching an estimated USD 13,603.4 million by 2032. This monumental leap reflects the sector's robust growth trajectory and its integral role in shaping the future of healthcare.
CAGR Odyssey: Charting a Course of Sustained Growth
At the heart of this surge lies a compelling Compound Annual Growth Rate (CAGR) of 16.25%. Between 2023 and 2032, the market is slated to experience an exponential expansion, marking an era of sustained growth and groundbreaking innovations.
Considering its potential to treat cancer, cell and gene therapy has sparked a lot of interest. With a complicated and expanding sector, a Contract Development and Manufacturing Company (CDMO) may assist customers in smoothing commercial cell and gene therapy manufacturing market needs.
In August 2022, Cytiva, a subsidiary of Danaher Corporation, and Forecyte Bio, a provider of CDMO service designed for cell gene therapy, collaborated to accelerate the development and manufacturing of cell and gene therapies in China and the U.S. Forecyte Bio will use Cytiva’s Flex Factory platform to launch its contract development and manufacturing organization (CDMO) business.
Ill effects of COVID-19 on the Cell and Gene Therapy Manufacturing Market
Due to the COVID-19 pandemic, players in the worldwide cell therapy manufacturing industry are experiencing significant hurdles on several fronts. The key obstacles are raw material availability owing to transportation facility inconsistencies. Furthermore, because of the increased prevalence of COVID -19, distributors are experiencing unpredictable demand for products from merchants.
However, there has been a modest positive influence on the market since cell therapies for the treatment of COVID-19 are being researched.
According to a Springer Nature article, mesenchymal cells (MSCs) are now being explored as one of the therapeutic strategies for COVID-19 illness. Researchers utilize immunosuppressive medications (Tocilizumab) to treat COVID-19 symptoms in patients; these cells can greatly improve critical circumstances due to their mode of action.
Influencers Fueling the Current Market Scenario
Key Players are involved in developing and launching various types of technologies for cell therapy manufacturing, which is expected to provide immense growth opportunities for industry players in the cell therapy manufacturing market. Manufacturers of cell therapy product candidates are engaged in receiving regulatory approvals to enhance their
cell therapy manufacturing process, which in turn is expected to drive the cell therapy manufacturing market growth
Hurdles Faced During Market Growth
One of the most significant issues is the high cost of cell treatments, which has financial consequences for patients, payers, and providers. As a result, firms must lower their pricing in order to increase the acceptance of these medicines, which is projected to hamper market growth throughout the forecast period.
Open Doors for the Cell and Gene Therapy Manufacturing Market
Soon, the cell therapy manufacturing market is likely to rise due to increased investment by major companies in the development of improved cell treatments.
For instance, in January 2022, Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, announced the completion of a Series A financing of US$ 80 million, led by the impact investment arm of Bayer AG —Leaps by Bayer— 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining existing investors The Engine and Khosla Ventures. The company has raised a total of US$ 96 million in gross proceeds from private financings.
Market Scope and Categorization of the Cell and Gene Therapy Manufacturing Market
The allogeneic cell therapy segment is estimated to be valued at US$ 1,198.2 Mn in 2022 and is expected to reach US$ 3,129.6 Mn by 2030 at a CAGR of 12.8%.
The somatic cell technology segment is estimated to be valued at US$ 823.2 Mn in 2022 and is expected to reach US$ 2,345.6 Mn by 2030 at a CAGR of 14.0%.
IPSC’s (Induced pluripotent stem cell) segment is estimated to be valued at US$ 1,092.5 Mn in 2022 and is expected to reach US$ 4,092.3 Mn by 2030 at a CAGR of 17.9%.
The musculoskeletal segment is estimated to be valued at US$ 807.3 Mn in 2022 and is expected to reach US$ 2,740.2 Mn by 2030 at a CAGR of 16.5%
The North American cell therapy manufacturing market is estimated to be valued at US$ 1,326.8 Mn in 2022 and is projected to increase to US$ 4,202.0 Mn by 2030, witnessing a CAGR of 15.5% between 2022 and 2030.
Global Cell Therapy Manufacturing Market Shere, By Region, 2022 and 2030
| Region |
Global Cell Therapy Manufacturing Market Shere, By Region, 2022 |
Global Cell Therapy Manufacturing Market Shere, By Region, 2030 |
| North America |
35.30% |
36.10% |
| Lattin America |
6.10% |
4.90% |
| Europe |
28.10% |
24.80% |
| Asia Pacific |
25.80% |
30.90% |
| Middle East |
3.40% |
2.50% |
| Africa |
1.20% |
0.80% |
Major key players’ strategic initiatives for shaping business growth
| Key Players |
Strategies |
| Partnership |
On June 15, 2022, WuXi Advanced Therapies, Contract Testing, Development, and Manufacturing Organization (CTDMO) business unit of WuXi AppTec. and Wugen Inc., a clinical-stage biotechnology company, announced a partnership to manufacture Wugen's WU-NK-101, novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancer. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients. |
| Announcement |
In May, WuXi Advanced Therapies, a contract development and manufacturing organization (CDMO) of WuXi AppTec., announced that it had expanded its service capabilities to offer a fully integrated, closed-process CAR-T cell therapy platform. This new platform will shorten the timeframe for developing, manufacturing, and delivering cell and gene therapies while providing better predictability. |
| Rebranding |
In July 2019, BioTime, Inc. announced that it had introduced a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, Inc. effective from August 12, 2019. The company also relocated its corporate headquarters to Carlsbad, California, effective August 12, 2019. |
| Collaboration |
In June 2018, BioTime Inc. company entered into an agreement with Athersys, Inc., a biotechnology company, for expanding its collaboration in additional therapeutic areas |
| Acquisition |
In October 2019, Merck KGaA announced that it had acquired FloDesign Sonics of Wilbraham, Massachusetts, a developer of a unique acoustic cell processing platform, for the industrialization of cell and gene therapy
manufacturing |
| Agreement |
On June 21, 2021, Takara Bio Inc. announced that it had entered into a license and supply agreement with BioNTech, a Germany-based biotechnology company. Takara Bio grants BioNTech a commercial license to use applicable patents relating to RetroNectin. Under this agreement, Takara Bio provides BioNTech with reliable supplies of RetroNectin, which can be used to manufacture cell and gene therapy products. |
